SCHEMBL19286751

SCHEMBL19286751

CC(C)(C)NC(=O)C(C)(C)CCC(C)(C)c1cn(C(C)(C)C)nn1

nearest known ligand 0.32

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.30
ALDH1A1 P00352 1/20 0.30
HTT P42858 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25485199 0.81 AR (0.30)
SCHEMBL20968408 0.73 KDM4E (0.35) KDM4EALDH1A1HTT
SCHEMBL19703658 0.73
SCHEMBL19704560 0.69 DPP4 (0.32)
SCHEMBL25977405 0.69 MAPT (0.34)
SCHEMBL22472680 0.68
SCHEMBL23127791 0.68
SCHEMBL25446419 0.67 SMN1; SMN2 (0.39) KDM4EALDH1A1HTT
SCHEMBL25155026 0.67 TSHR (0.34)
SCHEMBL21365276 0.66

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11725064-B2 Chimeric small molecules for the recruitment of antibodies to cancer cells YALE UNIVERSITY (US) 2023-08-15 US disclosed
US-20220023428-A1 CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-01-27 US disclosed
US-10633374-B2 Small molecule based antibody-recruiting compounds for cancer treatment YALE UNIVERSITY (US) 2020-04-28 US disclosed
US-9745334-B2 Cytotoxic-drug delivering molecules targeting HIV (CDM-Hs), cytotoxic activity against the human immunodeficiency virus and methods of use YALE UNIVERSITY (US) 2017-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11725064-B2 Chimeric small molecules for the recruitment of antibodies to cancer cells BRDT, PAICS, KLK3 KDM4E 971/4885ALDH1A1 2479/4885HTT 2925/4885
US-20220023428-A1 CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS BRDT, PAICS, KLK3 KDM4E 971/4885ALDH1A1 2479/4885HTT 2925/4885
US-10633374-B2 Small molecule based antibody-recruiting compounds for cancer treatment PLAUR, C5AR1, C3AR1 KDM4E 3381/4885ALDH1A1 3982/4885HTT 4470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.